MSD, the tradename of Merck & Co., will acquire Verona Pharma for $107 per American Depositary Share in a deal valued at roughly $10 billion, after the High Court of Justice of England and Wales sanctioned the scheme of arrangement. The transaction is expected to become effective on October 7, 2025, with Verona’s ADSs ceasing trading on Nasdaq ahead of market open that day. The acquisition brings Merck a newly launched COPD asset, ensifentrine, marketed as Ohtuvayre, and a focused respiratory portfolio under a UK corporate structure.
The strategic signal is clear: Merck is buying scale in chronic respiratory disease at a moment when the COPD market is being reconsidered clinically and economically. For a company seeking to diversify beyond oncology, a de-risked, in-market asset offers nearer-term revenue and a platform to re-enter a primary care–pulmonology arena long dominated by GSK, AstraZeneca, and Boehringer Ingelheim. The question for leadership teams across pharma is whether Merck can translate payer leverage and field muscle into a durable COPD franchise in a category defined by entrenched generics, fixed-dose triple therapies, and rising biologic ambitions.
This matters now because COPD management is under pressure to deliver measurable reductions in exacerbations, hospitalizations, and healthcare spend. For patients, a novel dual PDE3/4 mechanism with bronchodilatory and anti-inflammatory effects could expand options beyond LAMA/LABA/ICS regimens, particularly for symptomatic patients who remain uncontrolled. For payers, the crux will be comparative effectiveness and total cost of care: where does Ohtuvayre sit relative to generic inhalers and premium-priced triple therapies, and can real-world data substantiate claims on exacerbation reduction and functional outcomes? Depending on channel classification, a nebulized therapy may navigate different reimbursement dynamics between medical and pharmacy benefits, with implications for access, coding, and patient out-of-pocket costs. For HCPs, positioning and patient selection will be pivotal, as will adherence in a nebulized format versus handheld devices.
Commercially, Merck can bring scale to a launch that will require both payer sophistication and pulmonary specialty engagement. Expect emphasis on outcomes-based narratives and early health economic evidence, coupled with field medical activity to anchor Ohtuvayre’s place in treatment algorithms alongside standard bronchodilators and inhaled steroids. Lifecycle choices—such as device strategy, combinability with existing regimens, and potential label expansions—will determine how far the asset can stretch beyond a niche add-on. Merck’s integration speed, coding and reimbursement execution, and specialty pharmacy or DME channel design will be near-term differentiators.
The deal also underscores broader industry currents. Large-cap buyers are prioritizing late-stage and newly commercial assets with clearer line-of-sight to cash flows, often executing cross-border transactions via UK schemes to accelerate certainty. Respiratory is experiencing a reset, with new mechanisms in COPD, increased interest in chronic cough, and digital tools to track adherence and symptoms. As biologics push toward defined inflammatory subtypes in COPD and payers tighten utilization management, the bar for incremental value is rising, and evidence generation strategies are shifting toward pragmatic studies and hospital avoidance endpoints.
Watch the first six to twelve months for payer policy milestones, Medicare coding decisions, pulmonologist uptake, and early real-world effectiveness signals. If Merck can prove that Ohtuvayre meaningfully reduces exacerbations and system costs in everyday practice, it could reopen the COPD playbook. If not, the acquisition becomes a cautionary tale about the limits of scale against entrenched standards of care. Will this bet mark the start of a broader respiratory build-out—and can Merck bend a mature market toward novel mechanisms fast enough to matter?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
